Kim et al. conducted a phase 1/2a trial of autologous NK cells plus pembrolizumab vs. pembrolizumab monotherapy in patients with advanced NSCLC who had previously failed platinum-based chemotherapy and had a PD-L1 tumor score of at least 1% [141]. Here, CD274 is linked to neoplasm.